Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.80 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | PARP1 | P09874 | 1/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3179723 | 0.97 | CYP2C19 (0.76) | CYP2C19CYP3A4CYP2D6MEN1KMT2A | |
| SCHEMBL3181015 | 0.95 | CYP2C19 (0.74) | CYP2C19CYP3A4CYP2D6MEN1KMT2A | |
| SCHEMBL3173535 | 0.92 | CYP2C19 (0.70) | CYP2C19CYP3A4CYP2D6MEN1KMT2A | |
| SCHEMBL14068495 | 0.92 | CYP2C19 (0.70) | CYP2C19CYP3A4CYP2D6MEN1KMT2A | |
| SCHEMBL9884549 | 0.92 | CYP2C19 (0.70) | CYP2C19CYP3A4CYP2D6MEN1KMT2A | |
| SCHEMBL6206056 | 0.92 | CYP2C19 (0.70) | CYP2C19CYP3A4CYP2D6MEN1KMT2A | |
| SCHEMBL3181193 | 0.92 | CYP2C19 (0.70) | CYP2C19CYP3A4CYP2D6MEN1KMT2A | |
| SCHEMBL3175514 | 0.92 | CYP2C19 (0.70) | CYP2C19CYP3A4CYP2D6MEN1KMT2A | |
| SCHEMBL3997594 | 0.92 | CYP2C19 (0.70) | CYP2C19CYP3A4CYP2D6MEN1KMT2A | |
| SCHEMBL3704422 | 0.92 | CYP2C19 (0.74) | CYP2C19CYP3A4CYP2D6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022769-A1 | NOVEL POLYNITROGENATED SYSTEMS AS ANTI-HIV AGENTS | INSTITUT QUIMIC DE SARRIA CETS (ES) | 2010-01-28 | — | — | US | claimed |
| EP-2100890-A1 | NOVEL POLYNITROGENATED SYSTEMS AS ANTI-HIV AGENTS | Institut Quimic De Sarria Cets (ES) | 2009-09-16 | — | — | EP | claimed |
| US-20100022769-A1 | NOVEL POLYNITROGENATED SYSTEMS AS ANTI-HIV AGENTS | INSTITUT QUIMIC DE SARRIA CETS (ES) | 2010-01-28 | — | — | US | disclosed |
| EP-2100890-A1 | NOVEL POLYNITROGENATED SYSTEMS AS ANTI-HIV AGENTS | Institut Quimic De Sarria Cets (ES) | 2009-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022769-A1 | NOVEL POLYNITROGENATED SYSTEMS AS ANTI-HIV AGENTS | MSR1, CCR5, CD4 | CYP2C19 830/4885CYP3A4 397/4885CYP2D6 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.